Group 1: Research and Development Progress - The 3CL protease inhibitor project is in the preclinical research phase, developed in collaboration with Shaanxi University of Science and Technology [2] - The Qingfeng Hupai granules, based on traditional Chinese medicine, target mild COVID-19 symptoms and have been approved as a hospital preparation in Shaanxi Province [2][3] - The company signed a technical development contract with Shaanxi Traditional Chinese Medicine Research Institute to develop new herbal medicines for flu [3] Group 2: Product Development and Production - The company has expanded its production capabilities to include nine types of traditional Chinese medicine formulations, enhancing its competitive edge in hospital preparations [4] - The establishment of the Shaanxi Medical Institution Preparation Centralized Preparation Center has facilitated the signing of multiple processing agreements with medical institutions [4] - The company is developing transdermal drug delivery systems, including gel patches and hot melt adhesive patches, to enhance its product line [3] Group 3: Market Expansion and Sales Strategy - The company has established a comprehensive marketing network across 31 provinces, ensuring steady growth in performance [5] - The health product line includes six major categories, with significant sales growth driven by both online and offline channels [5] - The company is actively expanding into large supermarket markets and building specialized marketing teams [5] Group 4: Logistics and Distribution - The company’s pharmaceutical distribution network covers thousands of medical institutions in Shaanxi Province, ensuring comprehensive service delivery [6] - The company has obtained drug distribution rights through compliance with national quality management standards [6] - The logistics operations have seen steady growth, particularly during the pandemic, ensuring timely delivery of medical supplies [6] Group 5: Profitability and Future Planning - The company is focused on improving profitability through various strategies, including stabilizing raw material costs and optimizing product structure [6] - Plans include expanding the health business segment to create new profit growth points [6] - The company aims to enhance its research and development capabilities to foster innovative projects [6]

编号：2001-05-01 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | ...

编号：2021-08-02 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | ☑ 业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 | 通过" 同花顺路演平台 | "参与公司 2021 年半年度业绩说明会的广大投资者 | | 及人员姓名 | | | | 时间 | 2021 年 09 月 01 | 日（星期三） 15:00-16:30 | | 地点 | 同花顺 ...

编号：2021-08-01 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2001-07-01 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-12-07 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-09 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|----------------------------------------------------------|-------|-------| | | | | | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | | | | □媒体采访 | √ 业绩说明会 | ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-19 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------|--------------------------------------------------|--------------|-------|-------|-------|-------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | 特定对象调研 □分析师会议 | | | | ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-05 | --- | --- | --- | |--------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 10:00-11:00 | 华安证券、亚洲红马投资集团、中华出版促进会、熙德博远资 | | | 15:00-16:00 | 本、德邻众福投资、红土创新、申万菱信 华鑫证券、华泰证券、万家基金、英 ...